Skip to main content
|

Study of HER2-low and ultralow Metastatic Breast Cancer

Short Title: ENHERTU CSNDSI01


Enrollment Status: Recruiting

Specialty Area: Oncology

Condition Studied: Breast Cancer

Age Groups: Adult; Older Adult

Phase: Not Applicable


Study Information

Summary / Purpose

To capture real-world ENHERTU use and clinical data to guide understanding of HER2 testing in community oncology practices and evolving treatment options.

Study Type: Observational
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with HR+, HER2-low, and HER2-ultralow metestatic breast cancer
  • Received at least 2 cycles of treatment with ENHERTU

What's Involved

Participation in the study will include:
  • Sharing clinical data for research
  • No treatment is given as part of this study

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up